Disclosed herein are new peptide inhibitors against beta-lactam resistance that can improve the efficacy of currently available antibiotics. Methods of using the peptide inhibitors for treating bacterial infections are also disclosed.

The present invention related to the use of a composition comprising a pentapeptide as an active ingredient to suppress excessive sweating, to suppress body odor or to prevent or treat pain.

The present invention related to the use of a composition comprising a pentapeptide as an active ingredient to suppress excessive sweating, to suppress body odor or to prevent or treat pain.

The present invention provides phosphorylcholine conjugates and pharmaceutical compositions comprising same for the prevention or treatment of autoimmune diseases. In particular, the conjugates of the present invention are effective in treating autoimmune diseases associated with pathological inflammation.

The present invention provides phosphorylcholine conjugates and pharmaceutical compositions comprising same for the prevention or treatment of autoimmune diseases. In particular, the conjugates of the present invention are effective in treating autoimmune diseases associated with pathological inflammation.

The present invention relates to improved treatment of cancer, in particular to a treatment with a composition of CTL peptides for patients after a treatment with an immune checkpoint inhibitor.

The present invention relates to improved treatment of cancer, in particular to a treatment with a composition of CTL peptides for patients after a treatment with an immune checkpoint inhibitor.

Provided are a novel agent for inhibiting metastasis of human cancer cells, and a novel agent for determining whether target cells are cancer cells or not in a human. A human cancer cell metastasis inhibitor including human dicalcin or a partial peptide thereof, and a human cancer cell determination agent including human dicalcin or a partial peptide thereof.

Provided are a novel agent for inhibiting metastasis of human cancer cells, and a novel agent for determining whether target cells are cancer cells or not in a human. A human cancer cell metastasis inhibitor including human dicalcin or a partial peptide thereof, and a human cancer cell determination agent including human dicalcin or a partial peptide thereof.

The invention provides a method for treating one or more complications of diabetes in a mammal. The method comprises administering to a mammal in need thereof an effective amount of an aromatic-cationic peptide having at least one net positive charge; a minimum of four amino acids; a maximum of about twenty amino acids; a relationship between the minimum number of net positive charges (p.sub.m) and the total number of amino acid residues (r) wherein 3 p.sub.m is the largest number that is less than or equal to r+1; and a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (p.sub.t) wherein 2a is the largest number that is less than or equal to p.sub.t+1, except that when a is 1, p.sub.t may also be 1.